Julphar Holds 2025 Annual General Meeting and Elects New Board of Directors

Ras Al Khaimah, April 2026 – Gulf Pharmaceutical Industries – Julphar held its Annual General Meeting, where it discussed a strong financial performance for the fiscal year ended December 31, 2025. The financial statements showed a growth in revenue from continuing operations of 8.4% to reach AED 1,075.5 million, compared to the previous year. Profitability indicators also recorded a qualitative leap, as net profit reached AED 173.3 million, supported by an operating profit from continuing operations of AED 43.9 million, while earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 22.2% to reach AED 109.4 million, reflecting a tangible improvement in administrative and financial efficiency.

During the meeting, the Chairman of the Board of Directors of Julphar, Sheikh Saqer bin Humaid Al Qasimi, stated: "These distinguished results that we achieved during the year 2025 clearly reflect the success of the strategic direction we adopted, and our commitment to creating long-term sustainable value for our shareholders. The company has been able to maintain a solid financial position that supports our future ambitions, an achievement that would not have been possible without the great trust of our shareholders and the hard work of our loyal team. We look to the year 2026 and beyond with new horizons and great optimism, determined to continue the path of progress to enhance our leading position in the pharmaceutical industry regionally."

The CEO of Julphar, Mr. Basel Ziyadeh, added: "Julphar has shown exceptional resilience in adapting to market variables, as we focused primarily on innovation and expanding the scope of our geographical presence. During the past year, we succeeded in registering 14 new products in the United Arab Emirates and 25 registrations in international markets, steps that are fully consistent with the 2030 growth strategy. We aim in the next phase to strengthen our strategic partnerships and develop our product portfolio to meet the needs of patients in developing markets, with a continuous focus on raising quality standards and operational efficiency to ensure responsible and sustainable growth."

The meeting also witnessed the election of a new Board of Directors for the current term, to lead the next phase of the company's strategic transformation journey according to new leadership visions that support Julphar's ambitions, and shareholders expressed their confidence in the ability of the elected Board to continue achieving sustainable value. The General Assembly concluded its proceedings by emphasizing that the company will move forward on the path of pharmaceutical innovation, with full commitment to serving the community and providing reliable health solutions that contribute to improving the quality of life. This integrated vision reflects Julphar's determination to continue on its upward growth path, and to enhance its role as a fundamental pillar in the healthcare sector and the pharmaceutical industry in the region.